News & Events

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Inside Setidegrasib’s Phase 3 Development: Targeting KRAS G12D Through Protein Degradation

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

Why KRAS G12C May Drive a Survival Benefit With Cemiplimab in NSCLC

EMPOWER-Lung 1 Outcomes in KRAS G12C NSCLC

EMPOWER-Lung 1 Outcomes in KRAS G12C NSCLC

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Astellas begins patient dosing in phase 3 study of setidegrasib in previously treated KRAS G12D- mutated advanced non-small cell lung cancer

Astellas begins patient dosing in phase 3 study of setidegrasib in previously treated KRAS G12D- mutated advanced non-small cell lung cancer

How KRAS G12C Data Should Shape Combination Trial Design

How KRAS G12C Data Should Shape Combination Trial Design